During Q3 2018 the big money sentiment increased to 1.71. That’s change of 0.49, from 2018Q2’s 1.22. 9 investors sold all, 8 reduced holdings as AcelRx Pharmaceuticals, Inc. ratio is positive. 17 increased stakes while 12 funds took stakes. Funds hold 6.40 million shares thus 42.63% more from 2018Q2’s 4.49 million shares.
Moreover, Jpmorgan Chase has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 25,606 shs. Fmr Ltd Liability holds 226,844 shs. State Street Corporation owns 53,161 shs for 0% of their capital. Schwab Charles Inc owns 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 14,700 shs. Geode Capital Lc reported 346,097 shs stake. Virtu Limited Liability holds 34,770 shs or 0% of its capital. Da Davidson And holds 67,500 shs. Art Ltd invested 0.01% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Citadel Advsr Limited Liability Corporation holds 0% or 109,562 shs. California-based Cornerstone Capital has invested 0.02% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Zpr Invest Mgmt has 11,299 shs. D E Shaw owns 180,438 shs or 0% of their US capital. Goldman Sachs holds 0% or 50,879 shs. Invesco Ltd invested 0% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Susquehanna International Gp Ltd Liability Partnership holds 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) or 243,026 shs.

AcelRx Pharmaceuticals, Inc. had 3 insider sales and 6 insider purchases since September 24, 2018. This’s net activity of $22,185. On Monday, November 19 $49,120 worth of stock was bought by Palmer Pamela P. On Thursday, November 15 Shares for $58,376 were bought by EDWARDS MARK G. $13,883 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was bought by ASADORIAN RAFFI. On Monday, October 15 Dasu Badri N had sold 28,351 shs worth $141,755. On Monday, September 24 $31,289 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was sold by Hamel Lawrence G.

On March, 14. Investors wait AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) to reveal its quarterly earnings, according to Faxor. This year’s earnings per share analyst estimate is expected to be $-0.20. That is 0.00 % compareed to $-0.2 earnings per share for last year. Last quarter $-0.21 earnings per share was reported. Analysts sees -4.76 % EPS growth this quarter. Ticker’s shares touched $3.2 during the last trading session after 1.84% change.AcelRx Pharmaceuticals, Inc. has 3.86M shares volume, 96.81% up from normal. ACRX is uptrending and has moved 48.44% since February 24, 2018. ACRX outperformed by 48.44% the S&P 500.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

In total 4 analysts cover AcelRx Pharmaceuticals (NASDAQ:ACRX). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:ACRX) has 100% bullish analysts. 4 are the (NASDAQ:ACRX)’s ratings reports on Feb 24, 2019 according to StockzIntelligence Inc. On Monday, October 15 the firm earned “Buy” rating by Jefferies. On Wednesday, October 10 the rating was maintained by Ladenburg Thalmann with “Buy”.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The firm is worth $244.46 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Last it reported negative earnings. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

For more AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) news released briefly go to: Benzinga.com, Seekingalpha.com, Benzinga.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “52 Stocks Moving In Friday’s Mid-Day Session – Benzinga” released on February 15, 2019, “FDA Ad Com backs AcelRx Pharma’s Dsuvia – Seeking Alpha” on October 12, 2018, “54 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” with a publish date: February 19, 2019, “Pre-Open Stock Movers 02/15: (TLND) (CBAY) (NVDA) Higher; (AKAO) (TRUE) (LOGM) Lower (more…) – StreetInsider.com” and the last “AcelRx Finally Has An AdCom Date. Time For A Run Up? – Seeking Alpha” with publication date: September 13, 2018.